share_log

10-Q: Q2 2024 Earnings Report

10-Q: Q2 2024 Earnings Report

10-Q：2024財年二季報
美股SEC公告 ·  2024/08/15 03:35

Moomoo AI 已提取核心訊息

Aclarion reported Q2 2024 financial results with revenue of $10,971, down 36% year-over-year from $17,072, primarily due to concluded clinical activities. The company ended the quarter with a cash balance of $1.2 million. Gross loss was $12,323 compared to a loss of $2,229 in Q2 2023, while operating expenses decreased 20% to $1.1 million.The company completed significant financing activities in early 2024, including a $3.0 million public offering in February and raising approximately $1.7 million through an equity line agreement. Operating expenses were reduced through lower personnel costs, D&O insurance premiums, and legal fees, though partially offset by increased investor relations and clinical trial investments.Management indicates current cash will fund operations into Q3 2024, approaching the September 2024 maturity of their unsecured note. The company will need to raise additional capital to continue funding technology development, with plans to secure such funding. Total liabilities decreased to $1.4 million as of June 30, 2024, from $3.2 million at year-end 2023.
Aclarion reported Q2 2024 financial results with revenue of $10,971, down 36% year-over-year from $17,072, primarily due to concluded clinical activities. The company ended the quarter with a cash balance of $1.2 million. Gross loss was $12,323 compared to a loss of $2,229 in Q2 2023, while operating expenses decreased 20% to $1.1 million.The company completed significant financing activities in early 2024, including a $3.0 million public offering in February and raising approximately $1.7 million through an equity line agreement. Operating expenses were reduced through lower personnel costs, D&O insurance premiums, and legal fees, though partially offset by increased investor relations and clinical trial investments.Management indicates current cash will fund operations into Q3 2024, approaching the September 2024 maturity of their unsecured note. The company will need to raise additional capital to continue funding technology development, with plans to secure such funding. Total liabilities decreased to $1.4 million as of June 30, 2024, from $3.2 million at year-end 2023.
Aclarion報告了2024年第二季度的財務結果，營業收入爲10,971美元，同比下降36%，去年同期爲17,072美元，主要由於臨牀活動的結束。公司在本季度末的現金餘額爲120萬美元。毛虧損爲12,323美元，而2023年第二季度的虧損爲2,229美元，營業費用降低了20%，至110萬美元。公司在2024年初完成了重大的融資活動，包括在2月份進行的300萬美元的公開發行，以及通過股權融資協議籌集的約170萬美元。營業費用通過降低人事成本、D&O保險費和法律費用得以減少，儘管部分被增加的投資者關係和臨牀試驗投資所抵消。管理層表示，目前的現金將支持運營直到2024年第三季度，接近2024年9月到期的無擔保票據。爲了繼續資助科技開發，公司需要籌集額外的資金，並計劃確保這些資金。至2024年6月30日，總負債從2023年年底的320萬美元減少至140萬美元。
Aclarion報告了2024年第二季度的財務結果，營業收入爲10,971美元，同比下降36%，去年同期爲17,072美元，主要由於臨牀活動的結束。公司在本季度末的現金餘額爲120萬美元。毛虧損爲12,323美元，而2023年第二季度的虧損爲2,229美元，營業費用降低了20%，至110萬美元。公司在2024年初完成了重大的融資活動，包括在2月份進行的300萬美元的公開發行，以及通過股權融資協議籌集的約170萬美元。營業費用通過降低人事成本、D&O保險費和法律費用得以減少，儘管部分被增加的投資者關係和臨牀試驗投資所抵消。管理層表示，目前的現金將支持運營直到2024年第三季度，接近2024年9月到期的無擔保票據。爲了繼續資助科技開發，公司需要籌集額外的資金，並計劃確保這些資金。至2024年6月30日，總負債從2023年年底的320萬美元減少至140萬美元。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Forian
    FORA
    -- 3.590
    Ontrak
    OTRK
    -- 1.5900
    Mangoceuticals
    MGRX
    -- 4.840
    DarioHealth
    DRIO
    -- 0.700
    VSee Health
    VSEE
    -- 1.870
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    重磅財報來襲！2025年中國資產前景如何？
    近期，Goldman Sachs、Morgan Stanley、Appaloosa LP等多家機構唱好中國資產。 🎙️討論： 1. Deepseek引發了中國資產的一輪上漲。你對未來市場的看法如何？ 2. 包括 $阿里巴巴 (BABA.US)$ 和 $嗶哩嗶哩 (BILI.US)$ 在 展开
    中國的資產重估引發熱議：牛友們在買什麼？